BRAF and melanoma: In addition, recurrent TERT (OMIM 187270) promoter (32 of 45 [71%]), TP53 (OMIM 191170; 12 of 45 [27%]), CDKN2A/B (OMIM 600160; 11 of 45 [24%]), and PTEN (OMIM 601728; 7 of 45 [16%]) alterations were also observed, consistent with extracranial melanoma molecular profiling.9 Of the recurrent alterations defining TCGA melanoma molecular groups, only BRAF status is therapeutically actionable,10 and we thus next focused on correlations with BRAF alteration within our sequencing cohort.